How Brave New World Is Sneaking Up On Us
By John Farrell,
Forbes
| 02. 28. 2016
Untitled Document
Paul Knoepfler is not a scientist given to alarmism, but it’s pretty clear from his informative new book that the Brave New World is already upon us.
GMO Sapiens: the Life-Changing Science of Designer Babies provides a comprehensive overview of the state of the art science, and what headline-grabbing breakthroughs we can expect in the very near future, perhaps in less than a year.
Genetically modified human embryos are likely to be implanted and brought to term in the U.K., where three-parent IVF has been approved. This is a limited form of genetic manipulation, aimed to help couples where the mother would pass on certain diseases due to faulty genes in the mitochondria, the cell’s energy centers. In the process, the nucleus of the mother’s egg cell is transferred to replace the nucleus of a donor whose own egg cells contain healthy mitochondria. In this way the couple can avoid passing on the mother’s disease bearing genes.
In China, we may see human embryos modified using the controversial new CRISPR-Cas 9 technology to bring children to term, also...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...